Highlights:
- Developer of CBD Based Treatments for Multiple Skin Care Applications.
- New e-Commerce & Marketing Team with Experienced Industry Veterans.
- Exclusive Worldwide Rights to Patented Shark Repellent Technologies.
- Novel Cannabidiol Aspartame Combination Treatment Significantly Reduces ISGA Score in Atopic Dermatitis.
- Exclusive Worldwide Rights for Unique Formulas Addressing Jellyfish and Man O' War Stings, Sea Lice, and Swimmer's Itch with 4 Patents-Pending.
- Double-Blind Placebo-Controlled Clinical Trial of JW-200 for the Treatment of Actinic Keratosis.
- Merger Partner Next Frontier's Executive Chairman Interviewed with Benzinga.
- JUPW Board Approval of $5.0 Million Share Buyback Program.
JUPW will present data for Jupiter's JW-300, a cannabidiol topical treatment for first degree burns, at SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology Conference to take place May 11-15, 2022 in Nashville, Tennessee.
In a clinical trial of 36 patients, a controlled area of skin was exposed to UV irradiation. The percentage of subjects who experienced burns (measured by erythema) in patients treated with JW-300 was significantly lower (p=0.047) than in subjects who received the placebo lotion. The percent of subjects who were burned in the placebo arm was 61% compared to 27% in patients treated with JW-300. In addition, in patients (n=18) treated with JW-300, the average erythema score was 0.388 after radiation compared to 0.722 in the placebo arm (n=18).
Dr Glynn Wilson, Chief Scientist of Jupiter Wellness, commented, "These statistically significant results demonstrate JW-300's potential as either a prescription or over-the-counter topical cream to help prevent sunburn and its more harmful consequences such as skin cancer. We look forward to presenting these important data to leading dermatology and aesthetic medicine physicians at SCALE."
Jupiter CEO Brian John added, "JW-300 complements our current over-the-counter skincare products including CaniSun™ as well as our prescription product Photocil™, serving a large market that needs more effective solutions."
JUPW Recently announced it has concluded an Asset Purchase Agreement with Ascent Clinical Research, Inc. through which it has acquired certain clinical assets including clinical trial research contracts worth $3 million in annual revenues for a purchase price of 5% royalties on future net revenues generated by the assets.
About JUPW:
Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products. The JUPW clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. JUPW generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun™ sunscreen and other wellness brands sold through its robust distribution platform.
Over the past two years, JUPW has built a portfolio of award-winning wellness brands including CaniSun, Jack, Wellness 1937, Black Belt, and Felix Ambrosia, as well prescription therapeutics such as Photosil that have been featured in numerous media outlets including the Today Show, CNN, ABC, CBS, Animal Planet, AdWeek, Bloomberg, The Washington Post, Vogue, BuzzFeed, and Forbes.
JUPW to Launch CaniSun for Shark Defense Sunscreen with Patented Shark Repellents :
Exclusive Worldwide Rights to Patented Shark Repellent Technologies for the Sun and Skin Market Licensed from Shark Defense Technologies.
View Discovery Channel Videos on the Shark Repellent Technology Here: https://youtu.be/PM0YTlbx1qg
On April 7th JUPW announced the upcoming launch of CaniSun for Shark Defense™, the latest addition to the Company's reef-friendly sunscreen line. Through a licensing agreement with Shark Defense Technologies LLC, the leading researcher of chemical, electrochemical, and magnetic shark repellents, JUPW has the exclusive worldwide rights to patents, formulas, and production methods for shark repellent technologies for use in sun and skincare products.
Novel Treatment (JW-100) Significantly Reduces ISGA Score in Atopic Dermatitis: Results from a Randomized Double-Blinded Placebo-Controlled Interventional Study:
On April 6th JUPW announced the publication of clinical study results to investigate the safety and efficacy of JW-100, its proprietary lotion formulation for the treatment of atopic dermatitis (eczema) in the Journal of Cosmetic Dermatology, Vol. 21, Issue 4, April 2022, pp: 1647-1650.
JUPW Launches NoStingz Jellyfish Protective Sunscreen Backed by Patent-Pending Formula in $13 B Sunscreen Market :
Exclusive worldwide rights for unique formulas addressing jellyfish and man o' war stings, sea lice, and swimmer's itch with 4 patents-pending.
On April 5th JUPW announced the launch of NoStingz, a proprietary line of sunscreen designed to protect against jellyfish and man o' war stings, sea lice, and swimmer's itch all while continuing to protect ocean lovers' skin from UVA/UVB in a range of SPFs. JUPW has signed a license agreement with Shark Defense Technologies for the exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds including 4 patents pending. The agreement includes future collaboration to develop and refine additional formulas.
For more on The JUPW NoStingz product or to purchase visit: https://canisun.com/shop/nostingz-your-barrier-of-protection-from-sun-sea/
JUPW Board Approval of $5.0 Million Share Buyback Program:
On January 25th JUPW announced it its board of directors approved a $5.0 million share buyback program which expires on June 30, 2022. Under the Share Buyback Program, shares of JUPW common stock may be repurchased periodically in open market or privately negotiated transactions.
For additional information on Jupiter Wellness, Inc. (JUPW) visit www.jupiterwellnessinc.com.
The products mentioned are THC-free and/or compliant with the 2018 Farm Bill.
DISCLAIMER: This article is purely for informational purposes and is not a recommendation in any way for buying or selling stocks.
Media Contact
Company Name: Jupiter Wellness, Inc.
Contact Person: Brian John, CEO
Email: Send Email
Phone: (561)244-7100
Country: United States
Website: https://jupiterwellness.com/
